← All trials
NCT06457191
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 6, 2024
- Primary completion
- Aug 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- Jun 13, 2024
- Last posted
- Nov 12, 2024
- Enrollment
- 20
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CalgaryLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.